e-Cadherin in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Induced Parkinson Disease

Figure 1

Midbrain of untreated (control) or MPTP-treated (experimental) mice. The samples were treated as reported in Section 2. (a) Phase contrast images of substantia nigra, 10x magnification; (b) neurofilament 200 kDa (NF200) immunohistochemical staining, 4x magnification, (c) 20x magnification, and (d) 100x magnification. The arrows indicate the effect of MPTP treatment in the reduction of area with neurofilaments (a) and of length and thickness of neurofilaments (b, c, d).

(a)

(b)

(c)

(d)